Filing Flows › Zevra Therapeutics (ZVRA) › Who owns the stock
Who owns Zevra Therapeutics (ZVRA) stock
147 funds reported Zevra Therapeutics (ZVRA) shares in their latest 13F filings, worth $679M in all. The largest holder is BlackRock ($73.3M). Last quarter 83 funds added to their stakes and 48 cut them.
Largest holders (13F)
| Fund | Shares | Value | Change | Quarter |
|---|---|---|---|---|
| BlackRock | 5,108,871 | $73.3M | increase | 2026-06-30 |
| FMR LLC | 4,915,717 | $70.5M | increase | 2026-06-30 |
| Woodline Partners LP | 4,785,771 | $68.6M | increase | 2026-06-30 |
| Nantahala Capital Management, LLC | 3,594,952 | $51.6M | increase | 2026-06-30 |
| Vanguard Capital Management LLC | 2,638,910 | $37.8M | increase | 2026-06-30 |
| Vanguard Group | 3,305,207 | $29.6M | increase | 2025-12-31 |
| State Street | 1,681,999 | $24.1M | increase | 2026-06-30 |
| Geode Capital Management, LLC | 1,540,936 | $22.1M | increase | 2026-06-30 |
| D. E. Shaw | 1,306,949 | $18.7M | increase | 2026-06-30 |
| Qube Research & Technologies | 1,241,343 | $17.8M | increase | 2026-06-30 |
| Morgan Stanley | 1,203,875 | $17.3M | increase | 2026-06-30 |
| Legal & General Group | 1,201,668 | $17.2M | increase | 2026-06-30 |
| Dimensional Fund Advisors LP | 958,836 | $13.7M | increase | 2026-06-30 |
| Royce & Associates LP | 882,658 | $12.7M | decrease | 2026-06-30 |
| 683 Capital Management, LLC | 855,000 | $12.3M | decrease | 2026-06-30 |
Zevra Therapeutics' latest quarter
Zevra Therapeutics, Q3 2026: revenue $37.8M (+45% year over year), operating margin 30.7%, net earnings $19.2M, operating cash flow $10.0M. The chart follows the revenue to costs, profit and cash.
Questions
Who owns the most ZVRA stock?
By the latest 13F filings: BlackRock ($73.3M); FMR LLC ($70.5M); Woodline Partners LP ($68.6M); Nantahala Capital Management, LLC ($51.6M); Vanguard Capital Management LLC ($37.8M).
What is the short interest in ZVRA?
6,226,029 shares were sold short at the 2026-10-15 settlement, -12.89% of the float.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.